Clinical Trial Update: Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase II trial of transdermal estradiol for hormone-refractory prostate cancer was terminated; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Transdermal Estradiol (estradiol)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-12-24